US 10208073

I'll search for authoritative information on this specific patent number, including any litigation or appellate docket activity.

US Patent 10,208,073 — Summary

I searched for the specific number 10,208,073 and excluded near-number results. The following is grounded in the authoritative full text you supplied (Google Patents, fetched 2026-09-17) plus corroborating sources (USPTO/Google Patents bibliographic data, PubChem, Espacenet claims, DrugPatentWatch, CourtListener). Where I could not confirm something, I say so explicitly.

Bibliographic data

Abstract (verbatim): "Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy."

Technology context

The patent describes the chloride hydrochloride salt of fosnetupitant — an N-phosphonooxymethyl prodrug of netupitant, an NK₁ receptor antagonist — formulated as a solution with palonosetron hydrochloride (a 5-HT₃ antagonist) and used with dexamethasone. It corresponds to the IV product AKYNZEO (fosnetupitant chloride hydrochloride / palonosetron hydrochloride, NDA 210493). The specification discusses prodrug stability (the chloride-hydrochloride salt resisting reversion to the parent netupitant), one-step acid-free synthesis using chloromethyl dialkyl phosphate esters, rat and dog PK studies, and treatment of acute and delayed CINV.

Independent claims (plain language)

Claim 1 is the base claim; claims 10, 11, 12 and 13 are also independent (each is drafted as "A method for preventing…"). Claims 2–9 depend from claim 1; further dependent claims follow 12/13 (I did not capture every dependent claim, so I flag that below).

• Claim 1 — A method of preventing both acute and delayed nausea/vomiting in a human receiving highly emetogenic cancer chemotherapy. The patient is given, intravenously and before the chemotherapy, a solution containing: (i) a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant, (ii) a therapeutically effective amount of palonosetron hydrochloride, and (iii) this is in combination with a therapeutically effective amount of dexamethasone.

• Claim 10 — Same method as claim 1, additionally specifying: (a) fosnetupitant chloride HCl dosed 150–200 mg (measured as the netupitant portion of the molecule); (b) palonosetron HCl 0.25 mg (as free base); and (c) the solution concentration is 2–5 mg/mL (fosnetupitant chloride HCl, netupitant-portion basis).

• Claim 11 — Same as claim 10 but with the solution concentration being 5–15 mg/mL instead.

• Claim 12 — A "consisting of" (closed) version: IV administration of the fosnetupitant chloride HCl + palonosetron HCl solution in combination with dexamethasone, specifying (a) 150–200 mg fosnetupitant, (b) 0.25 mg palonosetron HCl free-base basis, (c) concentration 2–5 mg/mL, and (d) dexamethasone 12 mg orally day 1, then 8 mg orally each of days 2, 3 and 4.

• Claim 13 — Same as claim 12 but with the 5–15 mg/mL concentration range.

Examples of dependent claims: claim 2 (150–200 mg fosnetupitant + 0.25 mg palonosetron); claims 3 and 4 (2–5 mg/mL and 5–15 mg/mL concentrations respectively); claim 7 (dexamethasone 12/8/8/8 mg oral schedule); claim 9 (fosnetupitant independently prevents acute and delayed CINV).

Uncertainty: I have verbatim text for independent claims 1, 10, 11, 12, 13 and for dependent claims 2, 3, 4, 5, 7 and 9. I do not have authoritative text for dependent claims 6, 8, and 14+ (if any). I am not guessing at those.

Litigation / dockets (as of this search)

• No Federal Circuit appeal docket specifically for US 10,208,073 surfaced in my search. I could not confirm any CAFC 2026 appeal in which this patent is the patent-in-suit — I state this as a negative search result, not a certainty that none exists.
• The patent is identified as litigated in Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J., No. 3:22-cv-04635; the complaint (filed 07/18/2022) attaches US 10,208,073 as an exhibit. Google Patents also lists a related entry at 2:22-cv-04635. CourtListener hosts the docket (docket 63601016).
• Caution on look‑alike results: the well-known Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA line (Fed. Cir. 2017, aff'd SCOTUS 2019, 139 S. Ct. 628) concerns Helsinn's palonosetron formulation patents and the on-sale bar — it does not involve US 10,208,073. Likewise, the 2026 Delaware dismissal news item concerns Cinvanti (aprepitant) patents, and the PTAB/Azurity proceedings (instituted Nov. 19, 2025) concern US 8,623,826 / 9,183,357 / 9,943,515 / 10,828,297 — all different patents. Keep these separate from 10,208,073.

Provenance

• Full patent text: https://patents.google.com/patent/US10208073/en
• PubChem patent record: https://pubchem.ncbi.nlm.nih.gov/patent/US-10208073-B2
• Espacenet claims: https://hr.espacenet.com/publicationDetails/claims?DB=hr.espacenet.com&ND=4&locale=hr_HR&FT=D&date=20190219&CC=US&NR=[10208073B2](/patent/10208073B2)&KC=B2&tree=true
• DrugPatentWatch: https://www.drugpatentwatch.com/p/patent-claims/10208073 and https://www.drugpatentwatch.com/p/patent/10208073
• CourtListener (Gland Pharma complaint exhibit): https://www.courtlistener.com/docket/63601016/1/1/helsinn-healthcare-sa-v-gland-pharma-limited/authorities/

Interpretation rule applied: I treated "10208073" literally and did not substitute any similar number; note the title itself contains internal typographical quirks in the source text (e.g., "FOSNETUPTIANT" in the printed patent's title block; "phosphoncoxy" for "phosphonooxy"; a description range rendered "7 to 2 mg/ml"), which I can flag but cannot independently correct.

I'll research litigation involving US Patent 10208073 using the sources you specified.

Let me dig deeper into the specific case and its outcome.

Let me verify whether any other defendants were sued on this patent.

Litigation Involving U.S. Patent No. 10,208,073

Bottom line

Based on my searches of Google Patents' litigation metadata, Unified Patents' litigation portal, CourtListener/PACER dockets, DrugPatentWatch, ParagraphFour.com, IPWatchdog, and other public sources, only one litigation is known to have asserted U.S. Patent No. 10,208,073: Helsinn Healthcare S.A. v. Gland Pharma Limited in the U.S. District Court for the District of New Jersey. It was an ANDA/Paragraph IV case that was resolved by consent judgment/dismissal before any merits decision. I found no CAFC appeal and no PTAB (IPR/PGR) proceedings involving this patent.

Note the docket-number ambiguity: the action is reported both as 3:22-cv-04635 and 2:22-cv-04635. Gland's own counterclaim text (D.E. 25) refers to "Case No. 2:22-cv-04635," while the complaint and consent judgment caption it as "22-4635 (ZNQ)." The Google Patents page lists both numbers as separate New Jersey entries, which appears to be a data artifact of the same single action rather than two suits. I flag this rather than silently resolving it.

Case 1 — Helsinn Healthcare S.A. v. Gland Pharma Limited

The role of the '073 patent

The '073 patent is described in the complaint (Count VI) as one of the ten "Helsinn Patents," titled "Solution Comprising the Chloride Hydrochloride Salt of 4-(5-(2-(3,5-Bis(Trifluoromethyl)Phenyl)-N,2-Dimethylpropanamido)-4-(O-Tolyl)Pyridin-2-yl)-1-Methyl-1-((Phosphonooxy)Methyl)Piperazin-1-ium (Fosnetupitant) and Palonosetron Hydrochloride in Combination with Dexamethasone as a Neurokinin Receptor Modulator," issued February 19, 2019, with Helsinn as assignee. It is tagged in the Orange Book as a "use in combination with dexamethasone…" patent for Akynzeo® (NDA No. 210493), with listed expiration 2032-05-23.

Events giving rise to the suit

• Gland filed ANDA No. 217374 seeking approval for generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for IV administration.
• Gland sent Paragraph IV notice letters dated June 2, 2022 (all asserted patents except the '698) and July 11, 2022 (the '698 patent).
• Helsinn filed suit within the statutory window, asserting § 271(e)(2)(A) infringement and requesting an order under § 271(e)(4) delaying ANDA approval to the patents' expiration.

Defendant's response

Gland filed an Amended Answer and Counterclaims (D.E. 25, October 11, 2022), seeking declaratory judgments of non-infringement and invalidity as to all ten patents, including the '073 patent. Gland's invalidity defenses asserted §§ 101, 102, 103 and 112, and cited prior art including Bös (U.S. 6,479,483), WO 99/33846, DeGoey, Funk (U.S. 7,211,579), Krise I, Oslob, the ALOXI Label, and the EMEND Label. For the '073 patent specifically, Gland asserted a Sixth Affirmative Defense of invalidity and corresponding declaratory-judgment counterclaims.

Outcome

The parties reached an amicable resolution and submitted a Consent Judgment and Dismissal Order (letter to the court dated December 22, 2022). Key terms:

• Gland admitted that submission of ANDA No. 217374 was a technical act of infringement under 35 U.S.C. § 271(e)(2)(A).
• Gland did not rebut the statutory presumption of validity/enforceability (without prejudice to its invalidity defenses).
• Gland is enjoined from manufacturing, using, offering for sale, selling, or importing the generic product that is the subject of ANDA No. 217374 until a specified date (that date was redacted/sealed in the public version).
• Court retains jurisdiction to enforce.
• The case was marked closed; per DrugPatentWatch the termination date is December 23, 2022.

Discrepancy to flag: The docket entry text for D.E. 50 (Jan. 19, 2023) states claims were dismissed with prejudice, whereas the Consent Judgment text itself (D.E. 48/50) states claims, counterclaims, and affirmative defenses are "dismissed without prejudice." These two sources conflict; I am reporting both rather than resolving them.

Searches that found nothing

• No Federal Circuit appeal involving the '073 patent surfaced (consistent with the case never producing an appealable merits judgment).
• No PTAB IPR/PGR/CBM involving the '073 patent surfaced.
• No other district court litigation asserting the '073 patent was found. Other Helsinn Akynzeo®/Aloxi® litigations (e.g., against Teva, Dr. Reddy's, Sandoz, Sagent, and various other ANDA sponsors) concern other patents in the family (such as U.S. 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094), not the '073 patent.

Confidence and limitations

• High confidence that Helsinn v. Gland Pharma is the sole known litigation asserting the '073 patent, and that it ended in a consented dismissal without a merits ruling.
• Medium confidence on the exact docket number (2:22-cv-04635 vs. 3:22-cv-04635); the weight of the primary documents (complaint, consent judgment) supports 3:22-cv-04635 (ZNQ), with 2:22-cv-04635 appearing in Gland's counterclaim and in some databases.
• Uncertain as to the sealed licensed-entry date and the precise prejudice terms, for the reasons noted above.
• These results reflect publicly available databases and court filings accessible as of my searches; sealed settlement terms and any very recent filings may not be captured. If you need a definitive current docket, a direct PACER pull of 3:22-cv-04635 (D.N.J.) is the authoritative check.

I'll verify the "no proceedings on file" default against public sources before writing the report.

Let me confirm the scope of the Azurity IPRs and check for any challenge to the '073 patent or its immediate family.

PTAB / AIA Trial Proceedings — US Patent 10,208,073

Canonical source: the structured "PTAB proceedings on file" block (USPTO Open Data Portal ingest) — which returns no AIA trial proceedings for this patent. I independently re-ran this against PTAB E2E / the PTAB petitions portal, DrugPatentWatch's per-patent "PTAB cases" table, the Azurity institution decisions (which enumerate related matters), and general web search. All sources agree with the ODP block. I did not invent or infer any proceeding number.

Proceedings overview

Total: 0. Active 0 / claims invalidated 0 / claims sustained 0 / settled 0 / institution denied 0 — US 10,208,073 has never been challenged in an IPR, PGR, or CBM.

Bottom line for a defendant: there is no PTAB shortcut. Unlike the sibling Hel s family — where four separate Helsinn patents were instituted for trial on 2025-11-19 — the '073 patent is completely untested at the Board, all claims stand, and no petitioner has generated a Final Written Decision, a claim cancellation, or § 315(e)(2) estoppel you could ride on. If you want to invalidate this patent administratively, you would be first in line, and your petition would be evaluated on a clean slate with no § 325(d) "previously presented" history specific to this patent and no General Plastic follow-on risk.

Proceedings on US 10,208,073

None. There are no proceedings to list. I am stating this as a verified negative, not an absence of searching.

Adjacent proceedings you should know about (NOT proceedings on the '073 patent)

These are listed only so you don't misattribute them. None of these involves US 10,208,073, and none creates estoppel, a validity ruling, or claim-level disposition for the '073 patent.

IPR2025-00945 / -00946 / -00947 / -00948 / -00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (five petitions, filed concurrently)
• Filed: 2025-05-01 (accorded filing date 2025-05-01)
• Patents challenged — none is the '073 patent:
  • IPR2025-00945 → US 8,623,826
  • IPR2025-00946 → US 9,186,357
  • IPR2025-00947 → US 9,186,357 (disjoint claim sets; see the § 42.122 multiple-petition statement)
  • IPR2025-00948 → US 9,943,515
  • IPR2025-00949 → US 10,828,297
• Status: Institution granted 2025-11-19 for the proceedings as reported (the DrugPatentWatch per-drug "PTAB cases" table shows 9,186,357 and 10,828,297 as instituted 2025-11-19; the IPR2025-00948 institution decision expressly identifies all five as related). These are "Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting" patents of inventor Fabio Trento — i.e., the netupitant/palonosetron (NEPA) method patents, a different family from the fosnetupitant-salt solution claims of '073.
• Judge panel: IPR2025-00948 institution panel — Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher J. (third name truncated in the public copy I retrieved; I will not guess it).
• Petition grounds: § 103 obviousness only. Representative grounds (IPR2025-00947): Herrstedt, Bös, and optionally Herrington, ALOXI label, Hargreaves, and Bonadeo, in various combinations.
• Institution reasoning (from the IPR2025-00948 decision): the Board found a reasonable likelihood of prevailing on at least one challenged claim, and declined Helsinn's discretionary-denial arguments (which rested on "settled expectations" and § 325(d)).
• FWD / Appeal: none yet. Trial deadlines run from institution; no CAFC docket exists for these.
• Defensive value for you: Zero as to '073. The prior art Azurity assembled (Herrstedt/Bös/Herrington/ALOXI) attacks NEPA treatment-method claims, not the '073 claims, which are directed to a specific IV solution of fosnetupitant chloride hydrochloride + palonosetron HCl administered pre-chemotherapy in combination with dexamethasone for HEC-induced acute and delayed CINV. A '073 invalidity theory would need an art set aimed at that formulation/administration limitation.
• Caution — source discrepancies I will not paper over: (a) one earlier section of this analysis rendered a patent number as "9,183,357"; the correct number is US 9,186,357. (b) The IPR2025-00948 institution decision's related-matters paragraph contains an apparent typographical error listing "IPR2025-00048"; the correct number is IPR2025-00948.

Earlier, unrelated Helsinn IPRs (context only — different patents)

DrugPatentWatch records institution denials in IPRs against Helsinn's palonosetron formulation ("Liquid pharmaceutical formulations of palonosetron") patents — US 8,598,219 (Accord Healthcare, filed 2014-09, institution denied 2014-11-24), US 8,729,094 (Dr. Reddy's, filed 2015-07, institution denied 2015-10-14), and US 9,173,942 (Dr. Reddy's, filed 2016-02, institution denied 2016-08-17). Those patents are Aloxi-related and are not in the '073 family. They tell you nothing about '073's validity, though they do confirm that Helsinn's palonosetron-era patents have drawn repeat generic challenges.

Strategic summary

Claim-by-claim status. Every claim of US 10,208,073 — independent claims 1, 10, 11, 12, 13 and all dependent claims (2–9 as identified previously, plus any beyond the ones I could not verify) — is UNTESTED. There are no canceled claims, no sustained claims, no certificate-of-correction-driven narrowing, and no Board claim construction to lean on. For a defendant, "which claims survive?" is the wrong question: all of them do, as issued.

Estoppel landscape. Because no IPR/PGR was ever instituted on '073, no § 315(e)(2) estoppel attaches to this patent for any party or privy. Azurity's instituted IPRs on the '826/'357/'515/'297 patents create estoppel only as to those patents' grounds. Practically, that means: (i) you are free to raise any § 102/§ 103 ground against '073 in district court, including art that would otherwise have been IPR-eligible; and (ii) conversely, you get no free ride — there is no prior petitioner whose work you can adopt or whose estoppel you can wait out. Note also that the prior litigation over '073 (Helsinn v. Gland, D.N.J. No. 3:22-cv-04635, terminated by consent judgment/dismissal — see the earlier section of this analysis) produced no merits ruling, so no issue preclusion and nothing beyond a redacted licensed-entry date.

Pattern signals. (a) The same petitioner — Azurity — is running a coordinated five-petition campaign against Helsinn's NEPA patents, not against '073. (b) Helsinn fights PTAB challenges hard: it filed discretionary-denial briefs in each Azurity IPR invoking settled expectations and § 325(d), and it retained heavyweight experts (Navari for Helsinn; Peroutka for Azurity). (c) There is no defensive aggregator (e.g., Unified Patents) in the '073 chain. (d) Helsinn does not appear to have appealed any PTAB loss on the NEPA family, because it has not lost one. Combined with the Gland consent judgment, Helsinn's revealed posture is settle rather than litigate to judgment on these Akynzeo patents — which is itself a negotiating datapoint.

Recommended next steps

1. If you are a defendant, the honest answer is: there is nothing to cite. There is no FWD, no institution decision, and no cancellation order for US 10,208,073 to quote or link. Do not let an adversary's demand letter imply otherwise. The patent's administrative record is clean.
2. If you are considering an IPR on '073, you would be the first petitioner. That removes General Plastic follow-on risk and removes most § 325(d) bite as to this patent — but note two real obstacles: (i) the Examiner allowed over Krise and the N-phosphonooxymethyl prodrug art (cited on the face of the patent), so you need art that is not merely cumulative of Krise/Bös/Funk/DeGoel/Oslob; and (ii) the claims are method-of-use claims tied to a specific salt form, a specific IV solution, and a dexamethasone combination for HEC, so a naked "prodrug of netupitant was known" theory will not reach them.
3. Statutory-clock check before you file: under 35 U.S.C. § 315(b), a petitioner served with a complaint alleging infringement of '073 must petition within one year of service. If you were served in a 2022-era wave (e.g., the Gland matter), that window has long closed for those parties; if you are newly served, mark the date.
4. Milestones — none to track: there are no active '073 proceedings, so there is no institution deadline, no oral hearing, and no § 316(a)(11) one-year FWD deadline.
5. Verify current status yourself before relying on this: the authoritative sources are USPTO PTAB E2E / the PTAB petitions portal (https://ptacts.uspto.gov/), the PTAB Decisions site (https://www.uspto.gov/patents/ptab/decisions), and for any appeal, the Federal Circuit docket and CourtListener. A direct E2E search on "10,208,073" is the definitive check; my result is a verified negative as of the ODP ingest reflected in this prompt.

Confidence: High that no AIA trial proceeding exists on US 10,208,073. Medium on the exact institution panel composition for the adjacent Azurity IPRs (one APJ name was truncated in the public copy I retrieved). I found no evidence of any ex parte reexamination of '073 either, but that is outside the ODP block's scope and I did not treat it as exhaustively searched.

I'll research the assignment record for US 10,208,073 across the sources specified.

Let me dig into the assignment records and the inventors' affiliations.

Let me try to pin down the reel/frame records and the Hamilton SA LLC entity.

Assignment & Ownership Analysis — US 10,208,073

Search limitation (stated up front, per operating rules): I could not retrieve granular reel/frame numbers or "correspondent of record" fields in this session. The USPTO Assignment Center index (assignmentcenter.uspto.gov / assignment.uspto.gov) exposes those fields, but my searches returned only the conveyance-level records as mirrored on Google Patents' legal-events feed. I therefore report the three recorded conveyances with their conveyance types, parties, and dates (which are consistent across the sources I retrieved), and I explicitly mark reel/frame and correspondent as not retrieved rather than inventing them. A direct USPTO Assignment Center query on patent number 10,208,073 is the authoritative source for those two fields.

Inventors

Per the printed patent front page (US 10,208,073 B2, "Inventors" field):

Pattern notes. Seven of eight inventors are CH/IT-based and cluster geographically with Helsinn's Lugano/Pazzallo R&D site — a normal vertically-integrated-pharma inventor profile. The one anomaly is Valentino J. Stella, a tenured academic chemist (KU) who is a repeat co-inventor with the Helsinn team across the whole fosnetupitant family (U.S. 8,895,586; 9,908,907; 10,717,721; 11,312,698; 12,071,421). That is an academic-consulting arrangement, not a portfolio fire-sale indicator. I found no evidence of inventors departing the original assignee within 12 months of filing — the same eight names recur on later Helsinn continuations through 2022, indicating a stable in-house team.

Original assignee

Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland. A privately held, third-generation family-owned specialty pharma company (founded 1976), HQ in Lugano, with operating subsidiaries in the U.S. and China, and an Irish manufacturing/development subsidiary, Helsinn Birex Pharmaceuticals Ltd.

• Product embodying the claims: Yes. The '073 patent is Orange-Book listed against AKYNZEO® IV (fosnetupitant chloride hydrochloride / palonosetron hydrochloride, NDA 210493), with the "use in combination with dexamethasone… highly emetogenic cancer chemotherapy" use code. The IV solution form (NDA 210493-002) was approved May 27, 2020.
• Primary line of business: Cancer supportive care and oncology/rare-disease therapeutics; commercial-stage biopharma.
• Current status: Operating. Helsinn closed a growth-financing agreement with Oberland Capital Management LLC, publicly announced January 10, 2023. This is an operating company, not a distressed or dissolved entity.

Assignment timeline

No assignment framework issue: the Assignment Center does present records for this patent — the chain is short and every event is a corporate-finance or original-assignment event. Reel/frame numbers and correspondent names were not retrieved in this session (see limitation above).

1. 2018-01-18 (executed) / recorded 2018-01-18 — Reel/frame not retrieved

   • Conveyance: Assignment (assignment of inventors' interest)
   • Assignor(s): Fadini, Luca; Manini, Peter; Pietra, Claudio; Giuliano, Claudio; Lovati, Emanuela; Cannella, Roberta; Venturini, Alessio; Stella, Valentino J.
   • Assignee: Helsinn Healthcare SA
   • Correspondent: not retrieved
   • Context: Original/confirmatory assignment — executed contemporaneously with the Jan 18, 2018 filing of continuation app. 15/874,325, vesting title in the operating company.

2. 2022-12-30 (recorded) — Reel/frame not retrieved

   • Conveyance: Security Interest (grant of security / collateral assignment — not a transfer of ownership)
   • Assignor(s): Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc. (i.e., the Helsinn obligor group)
   • Assignee / secured party: Hamilton SA LLC
   • Correspondent: not retrieved
   • Context: Securitization / financing collateral — grants a security interest in the patent as part of a group-level secured facility. Consistent with the Helsinn–Oberland Capital financing announced ~11 days later (Jan 10, 2023). Hamilton SA LLC is not the beneficial owner; it acts as secured party/collateral holder. (Whether "Hamilton SA LLC" is an Oberland Capital affiliate acting as collateral agent is plausible but not confirmed by anything I retrieved.)

3. 2023-09-20 (recorded) — Reel/frame not retrieved

   • Conveyance: Release by Secured Party (discharge of the security interest)
   • Assignor: Hamilton SA LLC
   • Assignee(s) / released parties: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
   • Correspondent: not retrieved
   • Context: Lien release — the security interest recorded nine months earlier is discharged, returning the chain to unencumbered ownership by the original assignee. (A release this soon after the grant can reflect collateral substitution, restructuring, or partial release of a collateral package; I flag the short interval rather than over-interpret it.)

Net ownership conclusion: Title has remained with Helsinn Healthcare SA at all times. The only non-Helsinn party ever to appear in the record, Hamilton SA LLC, appeared solely as a secured party, and was released. There has been no assignment of ownership to any third party.

Timeline diagram

timeline
    title Ownership of US 10208073
    2011 : Priority date
    2012 : PCT application filed
    2018 : Inventors assign to Helsinn Healthcare SA
         : Continuation application filed 15874325
    2019 : Patent granted
    2022 : Security interest granted to Hamilton SA LLC
         : Helsinn sues Gland Pharma over ANDA
    2023 : Hamilton SA LLC releases security interest

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The patent never moved from the operating company to a licensing-only LLC. Hamilton SA LLC appears only as a secured party (security interest recorded 2022-12-30), a collateral role, and it released the lien (2023-09-20). No "IP/Holdings/Licensing/Ventures" assignee ever took title.

2. Known asserter in the chain — Not present. No assignee or secured party matches any public NPE list (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Round Rock, Spangenberg entities, etc.). Helsinn Healthcare SA is a commercial biopharma; Hamilton SA LLC is a finance-side entity, not a litigant.

3. Repeat correspondent across the chain — Unclear / not retrievable. I could not retrieve the correspondent-of-record field for any of the three entries. No finding possible; this signal should be re-run against a direct Assignment Center pull.

4. Cascading transfers — Not present. Three recorded events over ~5.5 years, and two of them are a security grant and its release. No chained LLC-to-LLC sequence, no shared-address cluster.

5. Pre-litigation transfer — Not present. The first infringement suit (Helsinn v. Gland Pharma, D.N.J., filed 2022-07-18) precedes the only two post-issuance recordings. The 2022-12-30 security interest is dated after suit was filed, so it cannot have been arranged to set venue or standing for that suit.

6. Bankruptcy fire-sale — Not present. Helsinn Healthcare SA is operating and in 2023 announced growth financing (Oberland Capital) and a new CEO — the opposite of a Chapter 7/11 asset liquidation. No bankruptcy docket surfaced.

7. Privateering — Not present. No transfer of the patent to a non-practicing entity asserting on Helsinn's behalf. Helsinn asserts its own patents directly (it is the named plaintiff in the Gland Pharma action).

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. Ownership remains with the operating innovator.

Verdict

Operating-company assertion.

Justification: The only recorded ownership event is the 2018-01-18 inventors' assignment to Helsinn Healthcare SA, and title has stayed there; the two later entries are a security interest granted to Hamilton SA LLC (recorded 2022-12-30) and that lien's release (recorded 2023-09-20) — financing collateral, not ownership transfers. Helsinn is a product-shipping operating company (AKYNZEO® IV, NDA 210493) that asserted the '073 patent directly against an ANDA filer in Helsinn v. Gland Pharma, D.N.J. 3:22-cv-04635. Zero NPE signal elements are present in the retrieved record. The single unresolved item is the correspondent-of-record field, which I could not retrieve and which should be checked directly at the USPTO Assignment Center.

Verification link: https://assignmentcenter.uspto.gov/ (search patent number 10,208,073) — and the mirrored legal events at https://patents.google.com/patent/US10208073/en

Reminder of cross-reference: the earlier "Litigation summary" section is consistent with the above — the only suit naming this patent is the Gland Pharma ANDA case, resolved by consent judgment without a merits ruling. Per the Interpretation rule, I treated "10208073" literally and did not substitute near-number patents (e.g., 9,908,907; 10,717,721; 11,312,698), which share the same inventor team and assignee but have their own assignment records.

I'll research the specific patent 10208073 and its cited prior art references.

Let me look at the specific reference citations listed for this patent.

I have the key citation lists. Let me verify details on the specific cited references.

Prior Art Analysis — U.S. Patent No. 10,208,073 (US 15/874,325)

Scope and method

I pulled the patent's own "References Cited" (56) list (from the granted-PDF front page and the PubChem patent record, which mirror the USPTO data) and reconciled it against the Google Patents citation list. Both sources return the same 21 patent documents (13 U.S., 8 foreign) plus 8 non-patent-literature items. I treat "10208073" literally and did not substitute any similar number; note that the OCR of the front page shows a typo in the title ("FOSNETUPTIANT") which I preserve only as a quoted artifact.

Critical structural point for § 102 analysis. Every issued claim of the '073 patent is a method-of-treatment claim (independent claims 1, 10, 11, 12, 13 — each "A method for preventing acute and delayed nausea and vomiting…"; dependents 2–9 and 14+). For a single reference to anticipate under 35 U.S.C. § 102, it must disclose each and every element of the claim, arranged as claimed — here, (i) the chloride hydrochloride salt of fosnetupitant, (ii) palonosetron hydrochloride, (iii) in combination with dexamethasone, (iv) given intravenously and before (v) highly emetogenic chemotherapy, for (vi) both acute and delayed CINV. None of the cited references, taken alone, discloses that full combination-plus-regimen. The overwhelming majority of these citations are background/§ 103 (obviousness) references directed to (a) the netupitant 4-phenyl-pyridine chemotype, (b) N-phosphonooxymethyl prodrug chemistry generally, or (c) Roche process/chemistry patents. I say so explicitly rather than force-fitting a § 102 label onto them. Where a reference could genuinely be relied on under § 102 (chiefly § 102(a)(2)/(e)-type publication-date scenarios, or a reference that itself discloses a multi-drug CINV combination), I flag it.

A. U.S. patent citations (13)

B. Foreign patent citations (8)

C. Non-patent literature cited (relevant to the combination/prodrug)

• Krise, Stella et al. — three papers on N-phosphonooxymethyl prodrugs of tertiary amines: J. Med. Chem. 1999, 42, 3094–3100; J. Pharm. Sci. 88(9) Sep. 1999, 922–927; and 88(9) 928–932 ("In Vivo Evaluation… in Rats and Dogs"). → Key § 103 art for the prodrug moiety and the rat/dog PK paradigm in the '073 specification (not § 102).
• Giuliani et al., Bioorg. Med. Chem. 2011, 19, 2242–2251 ("Non-peptide NK receptor ligands based on the 4-phenylpyridine moiety") and Catalani et al., Bioorg. Med. Chem. Lett. 2011, 21, 6899–6904, and Hoffmann T. et al., Bioorg. Med. Chem. Lett. 2006, 16, 1362–1365 → § 103 chemotype art.
• Gesztesi et al., Anesthesiology 93(4), 931–937 (2000) and Kramer et al., Science 281, 1640–1645 (1998) → § 103 background on NK₁ antagonists for emesis; expressly cited in the '073 background. Neither discloses the claimed three-drug IV regimen.

D. Bottom line — most relevant prior art

1. Strongest § 103 (obviousness) combination: US 6,297,375 / US 6,479,483 / WO 02/08232 / EP 1103545 (netupitant chemotype) + US 5,985,856 and the Krise papers (phosphonooxymethyl-prodrug chemistry). This is the combination that a challenger would most plausibly assert; it is why these appear in the file and why Gland pleaded §§ 102/103/112 against the '073 patent (see prior litigation section — Helsinn v. Gland, D.N.J.).

2. Closest thing to § 102 art: the only references that could theoretically be argued under § 102 are same-family disclosures (US 8,426,450; US 9,405,772; US 2017/0050993; WO 2013/082102), which are not "by another" and therefore not § 102 prior art against '073 — but they are the source of potential § 102(a)(2)/(e)-type issue only if one were attacking a later application, not this one. No independent third-party reference discloses the complete claimed method.

3. Explicitly-disclaimed art: US 6,747,026 (N-oxides) — the '073 disclosure "excludes all N-oxide forms," so it cannot anticipate.

Honest limitations: (a) I could not independently confirm the exact subject matter of US 6,303,780; 6,531,597; 6,593,472; 6,719,996; 6,806,370; 7,211,579; WO 2006/099968; WO 2009/138393; WO 2011/061622 in this pass, and I have not attributed specific disclosures to them beyond the Roche/Roche-family background characterization. (b) The front-page OCR shows "WO 2002205322 A1" where other databases show "WO 02/08232" — I flag rather than resolve this. (c) Because the '073 claims are combination method claims, no cited reference, standing alone, is a clean § 102 anticipation; a definitive § 102(e)/102(a)(2) and § 103 assessment would require the full text of each reference and is best confirmed against USPTO PatentCenter / the file wrapper (IFW) for application 15/874,325, which is the authoritative source.

I'll research the key prior art references relevant to this patent's claims before building the § 103 analysis.

I have strong grounding on the core prior art. Let me verify a few specific points: the fosaprepitant IV prodrug rationale, netupitant's known solubility/injectability problem, and whether any PTAB proceeding targets the '073 patent specifically.

Obviousness Analysis of U.S. Patent No. 10,208,073 under 35 U.S.C. § 103

This section builds on the previously generated Patent Summary and Litigation Summary. I do not repeat the bibliographic, claim-text, or docket content there; I use it as given, including the noted uncertainties (verbatim text obtained for independent claims 1, 10, 11, 12, 13 and dependent claims 2, 3, 4, 5, 7, 9; claims 6, 8, 14+ not verified). Where a conclusion depends on a claim I could not verify, I say so.

I. Legal standard applied

Obviousness is a question of law premised on the four Graham fact inquiries: (1) scope and content of the prior art; (2) differences between the prior art and the claims; (3) level of ordinary skill; and (4) objective indicia of non-obviousness. Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966). A claim is unpatentable if "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date" to a person of ordinary skill. 35 U.S.C. § 103 (pre-AIA, applicable here given the 2011 priority date). KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 418–19 (2007), confirms that an explicit teaching, suggestion, or motivation is not required — a reason to combine may come from "the effects of demands known to the design community," "the background knowledge possessed by a person having ordinary skill in the art," or "common sense." Also relevant: In re Aller, 220 F.2d 454 (CCPA 1955) (routine optimization); and the Federal Circuit's line holding that selection of a pharmaceutically acceptable salt is a predictable, routine exercise.

Because the '073 is a pre-AIA patent (priority 2011-11-29), §§ 102(a)/(b)/(e) govern which art qualifies. This matters, and I flag the edge cases in § VIII below.

II. Effective filing date and the prior-art window

The '073 claims a date of November 29, 2011 via provisional 61/564,537. Assuming the method claims (IV fosnetupitant chloride HCl + palonosetron HCl + dexamethasone for HEC CINV) are supported by that provisional, the § 103 prior-art window closes on 2011-11-29. Every reference used in the grounds below predates that date by at least three years:

Supporting URLs: Hesketh 2003, https://ascopubs.org/doi/abs/10.1200/JCO.2003.01.095 · Poli-Bigelli 2003 (Cochrane record), https://pmc.ncbi.nlm.nih.gov/articles/PMC8594936/table/CD012775-tblf-0073/ · Fosaprepitant reviews, https://www.tandfonline.com/doi/full/10.1586/14737140.8.11.1733 · Prodrug table (Nature Rev. Drug Discov. 2018), https://www.nature.com/articles/nrd.2018.46/tables/1 · U.S. 5,985,856, https://insight.rpxcorp.com/patent/[US5985856A](/patent/US5985856A).

Independent PTAB/Azurity IPR papers confirm these references were treated as § 102(b) art in challenges to Helsinn's related netupitant/palonosetron patents (e.g., the Azurity petition at https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835), and the parallel petition at https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf). Those proceedings target U.S. 8,623,826, 9,183,357, 9,943,515 and 10,828,297 — not the '073 (consistent with the Litigation Summary). I use them only as evidence of what the prior art taught, not as proceedings against the '073.

III. Person of ordinary skill in the art (POSA)

Consistent with the Azurity IPR record (which defined the POSA as a professional in "clinical medicine, medical oncology, … pharmacy, … and pharmacology" with advanced training and practical experience in "metabolism studies, in-vitro and in-vivo testing, formulation, and combination therapy"), the POSA here is a medicinal chemist / clinical pharmacologist with an advanced degree, familiar with: NK₁ receptor pharmacology; the then-current CINV treatment paradigm (5-HT₃ antagonist + corticosteroid ± NK₁ antagonist); prodrug design for solubility-limited drugs; and parenteral formulation and salt selection. The '073 specification itself concedes the art is mature ("The skilled artisan will be able to determine appropriate dosages," and the range "from about 1 to about 20 mg/ml").

IV. The prior art and what it teaches

A. The CINV triple regimen (NK₁ antagonist + 5-HT₃ antagonist + corticosteroid) was the established standard of care.

• Hesketh 2003 (APREPITANT Protocol 052) taught that adding aprepitant (NK₁ antagonist) to ondansetron + dexamethasone significantly improved complete response for highly emetogenic cisplatin-based chemotherapy across days 1–5, and expressly taught the dexamethasone taper 12 mg day 1 → 8 mg days 2–4, which is the exact schedule recited in '073 claims 7, 12 and 13.
• Poli-Bigelli 2003 taught the same triple combination with the identical dexamethasone regimen.
• Herrstedt 2007 generalized the class teaching: an NK₁ antagonist "increases the effect of a serotonin₃-receptor antagonist plus a corticosteroid against acute emesis induced by highly or moderately emetogenic chemotherapy," and is "also active in the protection against delayed emesis." Herrstedt also taught that adding an NK₁ antagonist to dexamethasone roughly doubles dexamethasone exposure (CYP3A4 inhibition) — i.e., the basis for dose-reduction of dexamethasone, which the '073 specification reproduces.

B. Netupitant was a known, superior alternative NK₁ antagonist.

• Bös / U.S. 6,297,375 discloses and claims 4-phenyl-pyridine NK₁ antagonists and expressly identifies netupitant ("compound Ib"/"formula Ib") as "a highly selective antagonist of the Neurokinin 1 (NK-1, substance P)," active against cisplatin-induced emesis and shown to "completely block[] the emesis induced by the emetogens" in ferrets. It teaches dosing "within wide limits" (10–1000 mg).
• Reddy 2006 taught that the 5-HT₃ antagonist + dexamethasone combination was the "standard of care for highly emetic chemotherapy" and that adding an NK₁ antagonist (aprepitant, casopitant) defined a new standard, while listing netupitant as an NK₁ antagonist under development for the same use. This is the very teaching the examiner relied on in the '826 family prosecution.
• Hoffmann (journal article, cited in the IPR record as Ex. 1011) lauded netupitant for high affinity and "excellent CNS penetration," positioning it as an improvement over aprepitant.

C. Palonosetron hydrochloride was a known, differentiated 5-HT₃ antagonist.

• The ALOXI label (2008) taught palonosetron HCl as a potent, selective 5-HT₃ antagonist, with an IV dose of 0.25 mg (free-base basis) and an oral 0.5 mg capsule, administered ~1 hour before chemotherapy, and taught administration with systemic corticosteroids such as dexamethasone. Herrstedt taught palonosetron's long half-life (~40 h) and its efficacy in delayed emesis as distinguishing it from other 5-HT₃ antagonists.

D. The prodrug strategy for a solubility-limited tertiary-amine drug was known and reduced to practice.

• U.S. 5,985,856 (Stella) claims "N-phosphoryloxymethyl prodrugs of tertiary amine containing drugs" and teaches their use "to improve the solubility profiles of loxapine and cinnarizine." The '073 specification itself cites the '856 patent and admits it "describes water soluble N-phosphoryloxymethyl derivatives of secondary and tertiary amines" — i.e., Helsinn concedes the prodrug chemistry.
• Fosaprepitant (EMEND for Injection / IVEMEND, approved 2008) is the reduction to practice in the very same drug class: an "N-phosphoryl prodrug" of the NK₁ antagonist aprepitant, "water-soluble," converted to aprepitant within 30 minutes by ubiquitous phosphatases, "improved solubility allowing intravenous administration" (Nature Reviews table; Navari 2008 review). Fosaprepitant was approved as the IV substitute on day 1 of the standard 3-day CINV regimen including dexamethasone and a 5-HT₃ antagonist.
• Fospropofol (LUSEDRA, 2008) independently confirmed "phosphonooxymethyl ester" prodrugs as a solubility-enhancement platform (propofol solubility raised from 150 µg/mL to ~500 mg/mL).

E. The problem the '073 addresses was expressly known. Netupitant's low aqueous solubility and the resulting infusion-site toxicity were known: early IV netupitant with polysorbate 80 "resulted in mild to moderate infusion-site thrombosis (thrombophlebitis) in 4 (67%) trial participants," and "netupitant cannot be injected due to its limited solubility" (Helsinn's own PTE submission, https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557835). The patent's own background frames the invention as the need for "enhanced physicochemical and/or biological properties."

V. Grounds of obviousness

Ground 1 — The claimed regimen is obvious over Herrstedt (or Hesketh) + Bös + ALOXI

Mapping to claim 1:

The only element not literally disclosed by this three-way combination is the quaternary N-phosphoryloxymethyl prodrug salt of netupitant. Put differently, if netupitant (the free base or oral form) were substituted for aprepitant in Hesketh/Herrstedt, Ground 1 would anticipate-independent, obvious subject matter for everything except the specific prodrug salt. That framing matters because the Federal Circuit has repeatedly held that substituting one known and equivalent member of a class (netupitant for aprepitant, both NK₁ antagonists acting by the same mechanism) is obvious where the art provides a reason (e.g., the Azurity petitions' Ground 1: "a POSA would have reasonably expected the combination to work similarly").

Ground 2 — Substituting netupitant for aprepitant was obvious

The motivation is strong and articulated in the art itself:

1. Same mechanism (NK₁ antagonism) and same therapeutic purpose (CINV) — KSR "predictable variation."
2. Bös '375 expressly identifies netupitant as a potent, selective, orally active NK₁ antagonist that blocks emesis in validated ferret/Suncus models — a reasonable expectation of success.
3. Hoffmann and Reddy add a further reason: netupitant's long half-life and high striatal NK₁ receptor occupancy (netupitant binds "in a long-lasting manner," less than 20–30% released at 96 h, per Helsinn's own later disclosures) relative to aprepitant's shorter duration — a recognized advantage for delayed CINV, the very phase the claim recites.
4. The '073 specification itself admits netupitant + palonosetron was "currently under clinical development … for the prevention of CINV by Helsinn Healthcare" as of the relevant time — confirming the combination was an obvious target.

Ground 3 — Selecting palonosetron (and its HCl salt) was obvious

Herrstedt 2007 taught palonosetron as the improved 5-HT₃ antagonist (long half-life; delayed-emesis efficacy). The ALOXI label fixed the HCl salt and the 0.25 mg IV dose, administered before chemotherapy. Selecting a member of the known 5-HT₃ antagonist class with the closest indication match is routine. The '073 specification goes further and expressly contemplates ondansetron, palonosetron, granisetron or tropisetron, calling out palonosetron as preferred — i.e., the inventors themselves treat the choice as a selection from a small, predictable group.

Ground 4 — The IV "solution" of the prodrug was obvious over Stella '856 + fosaprepitant (+ fospropofol)

This is the crux of claim 1's distinctive limitation (the N-phosphoryloxymethyl fosnetupitant entity and its presentation as a solution).

• Netupitant is a tertiary amine (its N-methyl-piperazine nitrogen is the reactive site). The '856 patent is directed precisely at "N-phosphoryloxymethyl prodrugs of tertiary amine containing drugs," giving the POSA the exact promoiety, the exact chemistry (nucleophilic displacement of a leaving group by the tertiary amine, then deprotection — see '856 claim 10), and the express rationale (improve aqueous solubility).
• Fosaprepitant is the same drug class and same therapeutic use, deliberately created as an N-phosphoryl prodrug to solve the same solubility/IV problem. Because aprepitant and netupitant share the class-defining NK₁-antagonist pharmacophore, the POSA would reasonably expect the prodrug strategy that worked for aprepitant to work for netupitant. This is a textbook "lead compound / bioisostere" obviousness posture.
• The POSA would also expect the prodrug to be cleaved in vivo to the parent (fosaprepitant: "converted to aprepitant within 30 min"), preserving the NK₁-antagonist efficacy already established for netupitant. The '073 specification confirms exactly this conversion ("rapidly and completely hydrolyzed to netupitant through the action of phosphatases and esterases").
• The "solution" limitation is met by routine formulation. ALOXI supplies an IV solution; fosaprepitant supplies an IV solution of an NK₁-antagonist prodrug. Reconstituting/co-formulating two IV-compatible actives in one solution is ordinary pharmaceutical practice. The claimed concentrations (2–5 or 5–15 mg/mL, claims 10/11/13) are squarely within the "about 10 mg/mL" the '073 specification itself says is routine, and within the range the art would reach by routine optimization.

I note that Stella '856's worked examples (loxapine, cinnarizine) are structurally dissimilar to netupitant and the '856 patent did not itself demonstrate netupitant. That is a legitimate counter-argument (see § VII/§ VIII), but KSR and the bioisostere line make structural dissimilarity weak where the chemistry (tertiary-amine phosphoryloxymethylation) and the problem (solubility for IV use) match, and where a same-class reduction to practice (fosaprepitant) exists.

Ground 5 — The "chloride hydrochloride" salt limitation is obvious as routine salt selection

Claim 1 requires the chloride hydrochloride salt specifically. The prior art is silent on this exact stoichiometric form, so this is a genuine difference. But:

• Hydrochloride is the most common pharmaceutically acceptable acid-addition salt; the '073 specification's own salt list leads with "hydrochloric" acid and lists HCl first among inorganic acids. Choosing an HCl salt of a basic N-phosphoryloxymethyl compound is routine optimization (In re Aller).
• The patent's asserted advantage — the chloride hydrochloride is "tremendously resistant to decoupling of the oxo-phosphonomethyl" and resists reversion to netupitant (FIG. 1 degradation curves) — is a stability rationale that a POSA would predictably pursue when developing an IV solution (stability being a routine formulation parameter). The existence of a favorable property does not by itself defeat obviousness unless the magnitude is unexpectedly beyond prediction.
• The '073 specification describes the salt as "a particular preferred compound" selected from the broader class; where the selection is from a small, recognized class (pharmaceutically acceptable salts of a disclosed compound) with a known purpose, the selection is presumptively obvious. Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007) (routine salt/form selection obvious absent unexpected results).

Caveat: Ground 5 is the weakest link and, if the chloride-hydrochloride salt produced an unexpected stability advantage of the magnitude the patent asserts, the patentee will point to FIG. 1 as objective evidence of non-obviousness. See § VII.

Ground 6 — Dosages and concentration (claims 10–13) are obvious by routine optimization

Claims 12 and 13 are drafted in "consisting of" form, but that closure does not add a patentable limitation beyond the already-obvious combination; the "consisting of" transition only limits the scope, it does not supply an element absent from the art. Under KSR, "a patent composed of several elements is not proved obvious merely by demonstrating that each of its elements was … known"; but where, as here, the elements are known, the combination is driven by the therapeutic objective, and the results are no more than the predictable sum of known effects, the claim is obvious.

VI. Motivation to combine and reasonable expectation of success

The motivations are mutually reinforcing and, importantly, are supplied by the prior art itself rather than by hindsight:

1. Efficacy ceiling of dual therapy. Hesketh 2003 and Poli-Bigelli 2003 quantified the need: adding an NK₁ antagonist to 5-HT₃ + corticosteroid raised CR from ~52% to ~73%. A POSA seeking to improve CINV control had a concrete, art-stated reason to keep an NK₁ antagonist in the regimen.
2. "Use the newer, better NK₁ antagonist." Bös '375 + Reddy + Hoffmann identify netupitant as a potent selective NK₁ antagonist with long receptor occupancy — the design-community demand for a longer-acting agent (especially for delayed emesis) that KSR treats as a reason to combine.
3. "Make it injectable." Netupitant's known insolubility and infusion-site toxicity created the motivation to convert it to an IV-compatible form; Stella '856 supplied the method (phosphoryloxymethylation of a tertiary amine); fosaprepitant supplied the same-class proof of concept (IV NK₁-antagonist prodrug).
4. "Pick a salt." Routine pharmaceutically acceptable salt screening (HCl first) supplies the chloride hydrochloride.
5. Reasonable expectation of success. Each step is a copy/carryover of a documented success in the same class: aprepitant→netupitant (same pharmacology), oral aprepitant→IV fosaprepitant (same prodrug rationale), palonosetron IV (approved dosing), dexamethasone 12/8/8/8 (approved schedule). The combination is the predictable aggregation of four known solutions.

VII. Secondary considerations the patentee will assert (and my assessment)

My assessment: the objective evidence could plausibly save the narrow salt-specific claims (claim 1 in its "chloride hydrochloride" form, and possibly claims 10–13 if the dose/concentration/salt combination is shown to be critical), but it does not rescue the genus-level inventive concept, which is squarely foreclosed by Hesketh/Herrstedt + Bös + Stella '856 + fosaprepitant.

VIII. Weaknesses, caveats, and where this analysis could fail

I flag these expressly rather than paper over them:

1. The strongest prior art (fosaprepitant) is a "method of making/using" analogue, not a literal identical compound. It teaches the strategy, not the molecule. A patentee will argue that the POSA had no specific reason to pick netupitant (as opposed to casopitant, L-733,060, etc.) for prodrug conversion because of netupitant's particular piperazine nitrogen environment, and that no reference demonstrates phosphoryloxymethylation of a 4-phenyl-pyridine NK₁ antagonist actually works. Counter: Stella '856 claims the class of tertiary-amine substrates, and netupitant is a plain tertiary amine; KSR makes the "which of many" argument unavailing when the art identifies the lead.

2. "Chloride hydrochloride" is a specific, non-preferred-looking stoichiometry. If the intrinsic evidence shows the dihydrochloride/chloride-hydrochloride form was non-routine (e.g., prior salt screens failed, or the form produces a crystalline/solution stability that other salts do not), claim 1's salt limitation could survive. This is the patentee's best § 103 defense.

3. Priority/support risk cuts both ways. If the '073's method claims are not entitled to 2011-11-29 (e.g., if the provisional disclosed only the compounds and not the IV/palonosetron/dexamethasone regimen), the effective date moves into 2012–2014. That could add art (e.g., Helsinn's own WO 2013/082102 and US 8,426,450 family publications) but could also disqualify art under § 102(b)/§ 102(a) timing. I could not verify the provisional's disclosure, so I do not rely on this. This is the single biggest uncertainty in my analysis.

4. Same-family references are not prior art. US 8,426,450 (parent of this family) and US 9,908,907/9,403,772 (same priority chain) disclose the fosnetupitant chloride hydrochloride and the IV regimen, but they share the '073's effective date and inventive chain and therefore cannot be § 102 art against the '073. I did not use them as art. (The related Helsinn patents US 8,623,826 and US 9,183,357 have a different priority basis — Nov. 18, 2009 — and different inventive entities (Trento et al.); whether they qualify as § 102(a)/(e) art against the '073 depends on common-ownership/inventive-entity analysis and the publication dates, which I could not fully resolve. They are, however, powerful evidence of what the field knew, and the Azurity IPRs already treat their subject matter as obvious over Hesketh/Herrstedt + Bös.)

5. Secondary-consideration record. The '073 specification contains FIG. 1 degradation data and PK tables, which the patentee can marshal. I could not independently verify the Fig. 1 magnitude or the comparator salts. If those data credibly demonstrate an unexpected stability ordering (chloride hydrochloride ≫ disodium and others), Ground 5 and the salt-specific claims are at risk.

6. Claims I could not verify (6, 8, 14+). Any claim reciting, e.g., a specific pH, a specific excipient (EDTA, mannitol), or a specific container would need separate analysis; those additions are frequently the subject of separate obviousness or § 112 arguments.

IX. Bottom line

• Claim 1, on its face, would likely be held obvious over the combination of Hesketh 2003 (and/or Herrstedt 2007) + Bös U.S. 6,297,375 + the ALOXI label + Stella U.S. 5,985,856 and fosaprepitant, with routine salt/formulation optimization supplying the chloride-hydrochloride/solution limitations. Every functional element (NK₁ antagonist + 5-HT₃ antagonist + dexamethasone; IV; pre-chemotherapy; HEC; acute and delayed) is expressly taught; the only arguable novelty is the specific prodrug salt entity, which the prodrug art and the same-class fosaprepitant reduction-to-practice render a predictable design choice.
• Claims 10 and 11 are additionally obvious as routine dose/concentration optimization (ALOXI 0.25 mg; Bös 10–1000 mg; the art's formulation concentrations).
• Claims 12 and 13 (closed "consisting of" versions) recite the dexamethasone schedule 12/8/8/8 verbatim from Hesketh 2003 and Poli-Bigelli 2003, and would be obvious for the same reasons; the "consisting of" transition restricts scope but adds no non-obvious element.
• The patentee's realistic path to survival is narrow: objective evidence (FIG. 1) showing that the chloride hydrochloride form gives an unexpectedly large stability benefit relative to other salts, with a clear nexus to the salt limitation. That argument, if strong, saves the salt-specific claims but not the underlying inventive concept.
• Weakest ground for a challenger: the salt limitation standing alone (Ground 5). Strongest grounds: Grounds 1–3 (the regimen and drug selections) and Ground 4 (the prodrug/IV strategy), which the same-class fosaprepitant art makes unusually clean.

Confidence: High on Grounds 1–4 and 6 (the art is express and same-class). Medium on Ground 5 (salt/stoichiometry is genuinely undisclosed by the art and depends on the strength of the patentee's stability data). Low/uncertain on the effective-filing-date issue (§ VIII.3), which I could not verify and which materially affects which art is available.

If you want, I can (a) pull the exact Fig. 1 data and comparator salt identities to grade the unexpected-results argument, (b) build a claim-chart for each Ground with pinpoint citations to the reference passages, or (c) check the 61/564,537 provisional disclosure to resolve the priority question in § VIII.3.